公开(公告)号：US20160151453A1

公开(公告)日：2016-06-02

申请号：US14906747

申请日：2014-07-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT PASTEUR DE LILLE ,  UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES ,  ETH ZURICH ,  UNIVERSIDAD DE LA REPUBLICA

发明人： Wolf-Dietrich HARDT ,  Patrick KAISER ,  Jean-Claude SIRARD ,  Christophe CARNOY ,  Delphine FOUGERON ,  Jose Alejandro CHABALGOITY ,  Natalia MUNOZ

IPC分类号： A61K38/16 ,  A61K31/505 ,  A61K31/42 ,  A61K31/43

CPC分类号： A61K38/164 ,  A61K31/42 ,  A61K31/43 ,  A61K31/505 ,  A61K31/635 ,  A61K45/06 ,  Y02A50/402 ,  Y02A50/475 ,  Y02A50/481 ,  A61K2300/00

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.

摘要翻译： 本发明涉及用于治疗细菌感染的方法和药物组合物。 特别地，本发明涉及用于治疗有需要的受试者的细菌感染的方法中的Toll样受体（TLR）激动剂，其中将TLR激动剂与至少一种 抗生素。

公开(公告)号：US20220218810A1

公开(公告)日：2022-07-14

申请号：US17595693

申请日：2020-05-28

申请人： ETH ZURICH

发明人： Emma WETTER ,  Médéric DIARD ,  Wolf-Dietrich HARDT

IPC分类号： A61K39/112 ,  A61K39/108 ,  C12N1/20 ,  C12N9/10

摘要： The present invention relates to an immunogenic composition for Proteobacteria protection and reduced transmission. We have identified Proteobacteria serovar variant combinations that generate an immune response capable of robustly driving bacterial enteropathogens into an evolutionary dead end and reducing the transmission of the bacterium. These inactivated immunogenic positions and typically oral vaccines are easy to apply, cheap to produce, and can be stored long-term without cold-chain requirements making them ideal for application in livestock, or in resource-poor areas. They are believed to be the only immunogenic compositions and vaccine formulations capable of breaking the chain of transmission for these types of pathogen.